[306 Pages Report] The global colorectal cancer molecular diagnostics market garnered a market value of US$ 2.35 Billion in 2022 and is expected to accumulate a market value of US$ 5.07 Billion by registering a CAGR of 8% in the assessment period 2022-2032. Growth of the market can be attributed to increasing cases of cancer along with development in diagnostic laboratories.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 2.17 Billion |
| Expected Market Value (2022) | US$ 2.35 Billion |
| Anticipated Forecast Value (2032) | US$ 5.07 Billion |
| Projected Growth Rate (2022 to 2032) | 8% CAGR |
Approximately 1.4 million new cases of colorectal cancer are diagnosed each year. Obtaining an early diagnosis is critical as it is currently one of the deadliest cancers, totalling more than 600,000 deaths each year.
Colorectal cancer molecular diagnostics can speed up the identification of colorectal cancer to provide patients with more treatment options. Individualized and targeted treatments are reshaping the colorectal molecular diagnostics market. Molecular pathology is a key factor in personalized medicine. This, in turn, is increasing the dependency on colorectal cancer molecular diagnostics.
Increasing adoption of high throughput sequencing technologies and identification of therapeutic targets has led to the development of many colorectal molecular diagnostic tests, which are superior to the conventional colorectal cancer molecular diagnostics tests.
Positive market trends and increasing investor confidence in several key players are helping mergers and acquisition activities in the colorectal cancer molecular diagnostics market. The disruption in the global healthcare market due to political factors such as the Obama Care Act, and regulatory framework changes, and other trade barriers, are anticipated to trigger merger and acquisition activities to drive the colorectal cancer molecular diagnostics market consolidation and further intensify the market competition.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increase in research in the pharmaceutical and biotechnology industry is contributing to the growth of the colorectal cancer molecular diagnostics market significantly. In addition, growing automation in laboratories is another factor supporting the growth of the colorectal cancer molecular diagnostics market.
Moreover, the ease of use of colorectal cancer molecular diagnostics, as well as accurate results is supporting the growth of the colorectal cancer molecular diagnostics market. All these factors are increasing the use of colorectal cancer molecular diagnostics.
Despite colorectal cancer being common across the globe, many people do not get themselves tested at an early stage. This is owing to the lack of knowledge regarding the problem and its lasting effects on health. In addition, the availability of low-cost alternatives and the high cost of instruments may hinder the growth of the market during the forecast period.
Limited specificity to some diagnostics tests that are unable to distinguish between inflammation and actual symptoms or cancer is another issue being faced by the colorectal cancer molecular diagnostics market.
Principal Consultant
American Cancer Society states that 52,580 deaths are expected to occur due to colorectal cancer in 2022 in U.S. the number of people being diagnosed with colorectal cancer is increasing owing to habits such as smoking, drastic diet changes and stress. Moreover, people suffering from hereditary cancer diseases are likely to suffer from cancer in the region. As the awareness regarding getting diagnosed is increasing, more people have shown an inclination to undergo tests. Furthermore, owing to the increasing automation of labs in the region is positively Inflcuening the growth of the market.
Thus, North America is expected to hold the maximum market share and is expected to register a CAGR of 9% for the global colorectal cancer molecular diagnostics market.
The strong and evolving government support towards research in biotechnology and pharmaceutical industry in Asia Pacific especially in countries like India and China are contributing to the growth of colorectal cancer molecular diagnostics. Reports state that the number of people suffering from colorectal cancer are expected to increase by 2035, especially in India.
Thus, the government of the country is taking measures to spread awareness amongst people to get tested at an early stage. The Asia Pacific colorectal cancer molecular diagnostics market is anticipated to grow at a rapid pace with a maximum CAGR of more than 8% over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key players in the global Colorectal Cancer Molecular Diagnostics market are Dako, Gen Probe (Hologic), Cepheid, Qiagen, Roche Diagnostics, Bayer Healthcare, Abbott Laboratories, Grifols, Guardant Health, Danaher Corporation, Siemens, Beckton Dickinson, Biomérieux Sa, and Sysmex Corporation. Attributed to the presence of such high number of participants, the market is highly competitive.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8% from 2022 to 2032 |
| Market Value in 2022 | US$ 2.35 Billion |
| Market Value in 2032 | US$ 5.07 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global colorectal cancer molecular diagnostics market to expand at an 8% value CAGR by 2032
North America is expected to be the most opportunistic colorectal cancer molecular diagnostics market, expanding at a 9% CAGR
Dako, Gen Probe (Hologic), Cepheid, Qiagen, Roche Diagnostics, Bayer Healthcare, Abbott Laboratories, Grifols, Danaher Corporation, Siemens, Beckton Dickinson, Biomérieux Sa, and Sysmex Corporation are some prominent colorectal cancer molecular diagnostics market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2022-2032
5.3.1. Colorectal Cancer Molecular Diagnostic Instruments
5.3.2. Colorectal Cancer Molecular Diagnostic Reagents & Kits
5.3.3. Services
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032
6. Global Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Technology
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Technology, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Technology, 2022-2032
6.3.1. PCR
6.3.2. Sequencing
6.3.3. Mass Spectrometry
6.3.4. Transcription Mediated Amplification
6.3.5. Chips and Microarrays
6.3.6. Isothermal Nucleic Acid Amplification Technology
6.4. Y-o-Y Growth Trend Analysis By Technology, 2017-2021
6.5. Absolute $ Opportunity Analysis By Technology, 2022-2032
7. Global Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Diagnostic Laboratories
7.3.4. Homecare Settings
7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
7.5. Absolute $ Opportunity Analysis By End User, 2022-2032
8. Global Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Technology
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Technology
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Technology
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Technology
10.3.4. By End User
10.4. Key Takeaways
11. Europe Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Product Type
11.2.3. By Technology
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Technology
11.3.4. By End User
11.4. Key Takeaways
12. East Asia Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Product Type
12.2.3. By Technology
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Technology
12.3.4. By End User
12.4. Key Takeaways
13. South Asia & Pacific Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Product Type
13.2.3. By Technology
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Technology
13.3.4. By End User
13.4. Key Takeaways
14. MEA Colorectal Cancer Molecular Diagnostics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of MEA
14.2.2. By Product Type
14.2.3. By Technology
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Technology
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Colorectal Cancer Molecular Diagnostics Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Product Type
15.1.2.2. By Technology
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Product Type
15.2.2.2. By Technology
15.2.2.3. By End User
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Product Type
15.3.2.2. By Technology
15.3.2.3. By End User
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Product Type
15.4.2.2. By Technology
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Product Type
15.5.2.2. By Technology
15.5.2.3. By End User
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Product Type
15.6.2.2. By Technology
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Product Type
15.7.2.2. By Technology
15.7.2.3. By End User
15.8. U.K.
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Product Type
15.8.2.2. By Technology
15.8.2.3. By End User
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Product Type
15.9.2.2. By Technology
15.9.2.3. By End User
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Product Type
15.10.2.2. By Technology
15.10.2.3. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Product Type
15.11.2.2. By Technology
15.11.2.3. By End User
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Product Type
15.12.2.2. By Technology
15.12.2.3. By End User
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Product Type
15.13.2.2. By Technology
15.13.2.3. By End User
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Product Type
15.14.2.2. By Technology
15.14.2.3. By End User
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Product Type
15.15.2.2. By Technology
15.15.2.3. By End User
15.16. ASEAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Product Type
15.16.2.2. By Technology
15.16.2.3. By End User
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Product Type
15.17.2.2. By Technology
15.17.2.3. By End User
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Product Type
15.18.2.2. By Technology
15.18.2.3. By End User
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Product Type
15.19.2.2. By Technology
15.19.2.3. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Product Type
15.20.2.2. By Technology
15.20.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product Type
16.3.3. By Technology
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Agilent Technologies
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Hologic
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Cepheid
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Qiagen
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Roche Diagnostics
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Bayer Healthcare
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Abbott Laboratories
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Grifols
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Danaher Corporation
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Siemens
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Beckton Dickinson
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. Biomérieux Sa
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. Sysmex Corporation
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Colorectal Cancer Molecular Diagnostics Market
